Mitoquinone/mitoquinol Mesylate As Oral and Safe Postexposure Prophylaxis for Covid-19

PHASE2RecruitingINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

SARS-CoV InfectionCOVID-19

Interventions

DRUG

Mitoquinone/mitoquinol mesylate

Mitochondrial antioxidant

OTHER

Placebo

Placebo pills

Trial Locations (1)

RECRUITING

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors

lead

University of Texas Southwestern Medical Center

OTHER